| PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer A Bosch, Z Li, A Bergamaschi, H Ellis, E Toska, A Prat, JJ Tao, DE Spratt, ... Science translational medicine 7 (283), 283ra51-283ra51, 2015 | 354 | 2015 |
| PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D E Toska, HU Osmanbeyoglu, P Castel, C Chan, RC Hendrickson, ... Science 355 (6331), 1324-1330, 2017 | 256 | 2017 |
| Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors N Vasan, P Razavi, JL Johnson, H Shao, H Shah, A Antoine, E Ladewig, ... Science 366 (6466), 714-723, 2019 | 236 | 2019 |
| PDK1-SGK1 signaling sustains AKT-independent mTORC1 activation and confers resistance to PI3Kα inhibition P Castel, H Ellis, R Bago, E Toska, P Razavi, FJ Carmona, S Kannan, ... Cancer cell 30 (2), 229-242, 2016 | 228 | 2016 |
| PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer A Glaviano, ASC Foo, HY Lam, KCH Yap, W Jacot, RH Jones, H Eng, ... Molecular cancer 22 (1), 138, 2023 | 198 | 2023 |
| Resistance to TRK inhibition mediated by convergent MAPK pathway activation E Cocco, AM Schram, A Kulick, S Misale, HH Won, R Yaeger, P Razavi, ... Nature medicine 25 (9), 1422-1427, 2019 | 183 | 2019 |
| ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer G Xu, S Chhangawala, E Cocco, P Razavi, Y Cai, JE Otto, L Ferrando, ... Nature genetics 52 (2), 198-207, 2020 | 159 | 2020 |
| Mechanisms of transcriptional regulation by WT1 (Wilms’ tumour 1) E Toska, SGE Roberts Biochemical Journal 461 (1), 15-32, 2014 | 146 | 2014 |
| Overview of the relevance of PI3K pathway in HR-positive breast cancer N Vasan, E Toska, M Scaltriti Annals of oncology 30, x3-x11, 2019 | 132 | 2019 |
| Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma P Mondello, S Tadros, M Teater, L Fontan, AY Chang, N Jain, H Yang, ... Cancer discovery 10 (3), 440-459, 2020 | 119 | 2020 |
| The present and future of PI3K inhibitors for cancer therapy P Castel, E Toska, JA Engelman, M Scaltriti Nature cancer 2 (6), 587-597, 2021 | 89 | 2021 |
| Repression of transcription by WT1-BASP1 requires the myristoylation of BASP1 and the PIP2-dependent recruitment of histone deacetylase E Toska, HA Campbell, J Shandilya, SJ Goodfellow, P Shore, KF Medler, ... Cell reports 2 (3), 462-469, 2012 | 89 | 2012 |
| FOXA1 mutations reveal distinct chromatin profiles and influence therapeutic response in breast cancer A Arruabarrena-Aristorena, JLV Maag, S Kittane, Y Cai, WR Karthaus, ... Cancer cell 38 (4), 534-550. e9, 2020 | 80 | 2020 |
| Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2) E Cocco, F Javier Carmona, P Razavi, HH Won, Y Cai, V Rossi, C Chan, ... Science signaling 11 (551), eaat9773, 2018 | 73 | 2018 |
| PI3K inhibition activates SGK1 via a feedback loop to promote chromatin-based regulation of ER-dependent gene expression E Toska, P Castel, S Chhangawala, A Arruabarrena-Aristorena, C Chan, ... Cell reports 27 (1), 294-306. e5, 2019 | 57 | 2019 |
| Presenilin influences glycogen synthase kinase-3 β (GSK-3β) for kinesin-1 and dynein function during axonal transport K Dolma, GJ Iacobucci, K Hong Zheng, J Shandilya, E Toska, JA White, ... Human molecular genetics 23 (5), 1121-1133, 2014 | 52 | 2014 |
| Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations P Mondello, EJ Brea, E De Stanchina, E Toska, AY Chang, M Fennell, ... JCI insight 2 (6), 2017 | 49 | 2017 |
| WT1 and its transcriptional cofactor BASP1 redirect the differentiation pathway of an established blood cell line SJ Goodfellow, MR Rebello, E Toska, LAH Zeef, SG Rudd, KF Medler, ... Biochemical Journal 435 (1), 113-125, 2011 | 47 | 2011 |
| TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors E Cocco, JE Lee, S Kannan, AM Schram, HH Won, S Shifman, A Kulick, ... Cancer discovery 11 (1), 126-141, 2021 | 43 | 2021 |
| Pancancer modelling predicts the context-specific impact of somatic mutations on transcriptional programs HU Osmanbeyoglu, E Toska, C Chan, J Baselga, CS Leslie Nature communications 8 (1), 14249, 2017 | 39 | 2017 |
Maurizio ScaltritiAstraZeneca在 astrazeneca.com 的电子邮件经过验证
